Celator Pharmaceuticals has raised $20 million in a series D round led by new investor Thomas, McNerney & Partners.
Alex Zisson
, a partner at the venture capital firm, will join Celator's board.
Proceeds from the financing will fund completion of ...
The US agency that runs Medicare – the Centers for Medicare and Medicaid Services (CMS) - has scheduled a 17 November advisory panel meeting to consider on-label and off-label use of Dendreon's prostate cancer treatment Provenge (sipuleucel-T). ...
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer.
The Japanese firm will pay undisclosed ...
Roche's Japanese subsidiary, Chugai , has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative surgery.
The submission follows a formal request ...
The US FDA has extended by three months the NDA review period for Eisai 's anticancer product eribulin mesylate. The agency now expects to complete its priority review for use in locally advanced or metastatic breast cancer on or before 30 ...
